In this study we observed that using kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS resulted in high rates of oocyte maturation, high implantation rates, and no clinically significant OHSS. The gene discussed is KISS1; the disease is ovarian hyperstimulation syndrome.